Nature Communications (Jan 2023)
Targeted systematic evolution of an RNA platform neutralizing DNMT1 function and controlling DNA methylation
- Carla L. Esposito,
- Ida Autiero,
- Annamaria Sandomenico,
- H. Li,
- Mahmoud A. Bassal,
- Maria L. Ibba,
- Dongfang Wang,
- Lucrezia Rinaldi,
- Simone Ummarino,
- Giulia Gaggi,
- Marta Borchiellini,
- Piotr Swiderski,
- Menotti Ruvo,
- Silvia Catuogno,
- Alexander K. Ebralidze,
- Marcin Kortylewski,
- Vittorio de Franciscis,
- Annalisa Di Ruscio
Affiliations
- Carla L. Esposito
- Institute for Experimental Endocrinology and Oncology “Gaetano Salvatore” (IEOS), CNR
- Ida Autiero
- Molecular Horizon
- Annamaria Sandomenico
- Institute of Biostructures and Bioimaging, CNR
- H. Li
- The Integrative Genomics Core, Beckman Research Institute, City of Hope Medical Center
- Mahmoud A. Bassal
- Cancer Science Institute of Singapore, National University of Singapore
- Maria L. Ibba
- Institute for Experimental Endocrinology and Oncology “Gaetano Salvatore” (IEOS), CNR
- Dongfang Wang
- Department of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center
- Lucrezia Rinaldi
- Harvard Medical School Initiative for RNA Medicine, Harvard Medical School
- Simone Ummarino
- Harvard Stem Cell Institute, Harvard Medical School
- Giulia Gaggi
- Harvard Medical School Initiative for RNA Medicine, Harvard Medical School
- Marta Borchiellini
- Department of Translational Medicine, University of Eastern Piedmont
- Piotr Swiderski
- Department of Cancer Biology and Molecular Medicine, Beckman Research Institute, City of Hope Medical Center
- Menotti Ruvo
- Institute of Biostructures and Bioimaging, CNR
- Silvia Catuogno
- Institute for Experimental Endocrinology and Oncology “Gaetano Salvatore” (IEOS), CNR
- Alexander K. Ebralidze
- Harvard Stem Cell Institute, Harvard Medical School
- Marcin Kortylewski
- Department of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center
- Vittorio de Franciscis
- Institute for Experimental Endocrinology and Oncology “Gaetano Salvatore” (IEOS), CNR
- Annalisa Di Ruscio
- Harvard Medical School Initiative for RNA Medicine, Harvard Medical School
- DOI
- https://doi.org/10.1038/s41467-022-35222-4
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 17
Abstract
Here the authors generate an RNA-based platform to neutralize the major epigenetic player DNMT1. Using this targeted approach, aberrant DNA methylation in cancer can be corrected.
